Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods-Reference-Cited by-同舟云学术

Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods

Published:2023-09-09 Issue:18 Volume:24 Page:13886
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Fogacci Federica¹^ORCID,Di Micoli Valentina¹,Avagimyan Ashot²^ORCID,Giovannini Marina¹,Imbalzano Egidio³^ORCID,Cicero Arrigo F. G.¹⁴^ORCID

Affiliation:

1. Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy

2. Pathological Anatomy Department, Yerevan State Medical University, Yerevan 0025, Armenia

3. Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy

4. Cardiovascular Medicine Unit, Heart, Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40100 Bologna, Italy

Abstract

Apolipoprotein(a) (apo(a)) is the protein component that defines lipoprotein(a) (Lp(a)) particles and is encoded by the LPA gene. The apo(a) is extremely heterogeneous in size due to the copy number variations in the kringle-IV type 2 (KIV2) domains. In this review, we aim to discuss the role of genetics in establishing Lp(a) as a risk factor for coronary heart disease (CHD) by examining a series of molecular biology techniques aimed at identifying the best strategy for a possible application in clinical research and practice, according to the current gold standard.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

https://www.mdpi.com/1422-0067/24/18/13886/pdf

Reference94 articles.

1. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target;Koschinsky;Atherosclerosis,2022

2. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective;Arsenault;Atherosclerosis,2022

3. Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: A dose-response meta-analysis;Wang;Eur. J. Med. Res.,2022

4. Association between Lipoprotein(a) and risk of atrial fibrillation: A Systematic Review and Meta-analysis of Mendelian Randomization Studies;Singh;Curr. Probl. Cardiol.,2023

5. Circulating lipoprotein (a) and all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis;Amiri;Eur. J. Epidemiol.,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?;Journal of Clinical Medicine;2024-01-28

2. Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting;Biomedicines;2023-12-12

3. Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab;Biomedicines;2023-12-11